Antisense Therapeutics has been granted a patent for a method to treat muscular dystrophy by administering an inhibitory oligonucleotide to human CD49d. The method involves periodically administering a pharmaceutical composition containing a specific oligonucleotide structure to improve limb muscle function or strength in patients. GlobalData’s report on Antisense Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Antisense Therapeutics, Nucleic acid active pharmaceutical ingredient was a key innovation area identified from patents. Antisense Therapeutics's grant share as of May 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating muscular dystrophy with inhibitory oligonucleotide
A recently granted patent (Publication Number: US11976281B2) discloses a method for improving limb muscle function or strength in individuals with muscular dystrophy (MD). The method involves administering a pharmaceutical composition containing a specific oligonucleotide structure at a therapeutically effective amount of 25 mg to 100 mg. The oligonucleotide comprises specific modifications and linkages to enhance its efficacy in improving limb muscle function. The periodic administration of this composition, once or twice per week, has shown promising results in delaying the decline in limb muscle function in individuals with various types of muscular dystrophy, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).
Furthermore, the patent claims cover the administration of the pharmaceutical composition in combination with corticosteroid treatment, at reduced doses compared to standard recommendations. The method allows for flexibility in dosing, with options for once or twice weekly administration at specific doses tailored to the individual's condition. The patent also specifies the types of muscular dystrophy covered under the method, including DMD, LGMD, BMD, CMD, and others, providing a comprehensive approach to improving limb muscle function in individuals with these conditions. Overall, the patent highlights a novel approach to managing muscular dystrophy by targeting limb muscle function and strength through the administration of a specific oligonucleotide composition, potentially offering new treatment options for individuals with these debilitating conditions.
To know more about GlobalData’s detailed insights on Antisense Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
